Psychedelic and nutraceutical interventions as therapeutic strategies for military-related mild traumatic brain injuries
Amy C. Reichelt, Eric Vermetten, Benjamin T. Dunkley
Journal of Military, Veteran and Family Health October 25, 2023 DOI: 10.3138/jmvfh-2022-0084 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Keywords | Concussion Traumatic brain injury Psychological intervention Intervention counseling Athletes Disease Nutraceutical Injury prevention Poison control Physical therapy Pathology Medical emergency |
| Citations | 5 |
| Key findings | Classic psychedelics and nutraceuticals may be combined as therapeutic strategies for treating concussions and persistent symptoms. |
Abstract
LAY SUMMARY Concussion is a type of acquired brain injury that is common in the military, as well as among civilians and contact sport athletes, and is defined by a transient impairment in mental function. Nevertheless, concussion presents a considerable health burden, and a small minority of people suffer from continued impairment. Repetitive sub-concussive head injury is a known risk factor for neurodegenerative disease, including dementias. Concussions are difficult to treat because symptom profiles vary, but psychedelic therapies may help address some of the neurological issues that occur after brain injury. Classic psychedelics show promise as an emerging pharmacological intervention because they appear to help the brain to rewire, and they have anti-inflammatory effects. Nutraceutical interventions are widely available, cost-effective, and well tolerated, and they could also support recovery when combined with psychedelic compounds. Here, studies presenting classical psychedelics and nutraceuticals that may be combined with psychedelics as therapeutic strategies for the treatment of concussions and persistent symptoms are discussed.
Citations in the library
Cited by 3
- Examining the potential of psilocybin and 5-MeO-DMT as therapeutics for traumatic brain injury. Progress in Neuro-Psychopharmacology and Biological Psychiatry July 14, 2025
- Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology British Journal of Pharmacology September 2, 2025
- Psilocybin restores behavior and 5-HT2A signaling while reducing microglial density after chronic traumatic brain injury in rats. Cell Reports Medicine June 12, 2026
Cites 24
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
- Psychedelics Promote Structural and Functional Neural Plasticity Cell Reports June 1, 2018
- Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine November 3, 2022
- Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo Neuron July 5, 2021
and 19 more in the library